Published in Medical Letter on the CDC and FDA, February 15th, 2004
Adding to the FDA's burden is an expanded mission to implement counter-bioterrorism activities, review increasingly complex new product applications, and expand postmarket safety vigilance, the Tufts Center reported in its recently released "Outlook 2004" report on drug and biotech development trends.
"FDA personnel and resources will be under growing stress to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.